NewsSynapse Electroceutical adds its support to calls for an NHS funding debate

Synapse Electroceutical adds its support to calls for an NHS funding debate

Service delivery

Synapse Electroceutical adds its support to calls for an NHS funding debateSynapse Electroceutical Ltd – manufacturers of Accel-Heal – supports the call on policy makers to hold a national conversation on the funding of the NHS, recently highlighted in a letter to the editor of The Times entitled We need a proper health policy conversation.

The letter from a panel of experts, ranging from RCNs Dr. Peter Carter and Dr. Maureen Barker of The Royal College of General Practitioners and including two NHS England non-executive directors; Ciaran Devane, chief executive of Macmillan Cancer Support, and Turning Point chief executive Lord Adebowale, calls for "an all-party-mandated, independently conducted national conversation on the scope, provision and funding of health and social care. It needs to start now and be completed by the end of next year". 

The experts say that "more has to be done to eliminate inefficiencies, wasteful variations in care and apply technology to transform care delivery. Business as usual won't do". 

Supporting the call for real change and a national conversation on how healthcare is delivered, Synapse Electroceutical's CEO, John Gildersleeve said: "Again we are seeing experts calling for removing inefficiency and for the application of technology to transform care delivery. Policy and decision makers in the wound care sector need to take note of this". He added "As a sector we cater for as many patients as cancer services but with a fraction of the resources. Commissioners across wound care in both primary and secondary care need to look at what is available to them to make delivery of wound care services more efficient, financially viable and focused on improving patient outcomes."

"Again we are being told that technology is one of the essential components. With an ageing population the forecast for the next 50 years being that of a growth of at least two and half times as many people suffering with complex and multiple conditions, is it not high time that policy makers and those in charge of service commissioning and delivery took note of what is being said?" Gildersleeve went on to ask.

Dr David Chapman-Jones, Synapse Electroceutical's Chief Scientific Officer highlighted the importance that SMEs play in the delivery of innovation, efficiency and improved outcomes to the  healthcare sector. "In our experience, in the wound care sector, small and medium sized enterprises contribute a huge amount to the NHS, providing real solutions to improving patient care and outcomes while reducing costs through innovative medical technologies like ours."

He added "Policy makers and commissioners need not look far to find appropriate, cost effective solutions to the ongoing funding issues within the NHS. As a sector we are not advocating shortcuts in demonstrating clinical efficacy. We have already invested considerable resources, conforming to existing standards and yet, despite demonstrating clinical efficacy, excellent health economics and better patient outcomes, there is still a problem with access to our product for committed clinicians caused by the existing frameworks.

This dialogue should not be about patients paying for certain healthcare services. It's time for policy makers and commissioners to move away from the comfort of 'business as usual' and look to innovative medical technologies like ours, incorporating those that can provide key components to the solution from within the SME sector".